"PGA"- Peg/Gem/Abraxane Should Rock- See ASCO Data
June 3, 2013, 12:30 p.m. EDT
Analyses of MPACT Trial Evaluating ABRAXANE(R) Combination Therapy for the Treatment of Advanced Pancreatic Cancer Presented at ASCO 2013
Data Suggest Treatment with ABRAXANE plus Gemcitabine Reduces Levels of CA19-9 and Increases the Frequency of PET Responses; Both Tools Found to be Potential Prognostic Factors of Overall Survival
The MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) overall trial results demonstrated that patients treated with ABRAXANE plus gemcitabine had a statistically significant improvement in overall survival compared with those treated with gemcitabine alone ...
Whogo's dead on target- PEG will Reduce side effects by enhancing Chemotherapy's activity- less will be required- we also know that Human Recombinant Hylenex itself bears no significanyt burden of adverse effects.